DK2734634T3 - Igf-1 til anvendelse til behandling af migræne - Google Patents
Igf-1 til anvendelse til behandling af migræne Download PDFInfo
- Publication number
- DK2734634T3 DK2734634T3 DK12817792.0T DK12817792T DK2734634T3 DK 2734634 T3 DK2734634 T3 DK 2734634T3 DK 12817792 T DK12817792 T DK 12817792T DK 2734634 T3 DK2734634 T3 DK 2734634T3
- Authority
- DK
- Denmark
- Prior art keywords
- igf
- migraine
- treatment
- Prior art date
Links
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161510673P | 2011-07-22 | 2011-07-22 | |
| PCT/US2012/047683 WO2013016223A2 (en) | 2011-07-22 | 2012-07-20 | Treatments for migraine and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2734634T3 true DK2734634T3 (da) | 2019-10-21 |
Family
ID=47601729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12817792.0T DK2734634T3 (da) | 2011-07-22 | 2012-07-20 | Igf-1 til anvendelse til behandling af migræne |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9399053B2 (da) |
| EP (2) | EP2734634B1 (da) |
| AU (4) | AU2012287120B2 (da) |
| DK (1) | DK2734634T3 (da) |
| ES (1) | ES2751388T3 (da) |
| PL (1) | PL2734634T3 (da) |
| WO (1) | WO2013016223A2 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014028763A1 (en) | 2012-08-15 | 2014-02-20 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
| US11389509B1 (en) * | 2017-07-12 | 2022-07-19 | University Of Virginia Patent Foundation | Methods for treatment of social dysfunction neurological disorders and seizures |
| EP4027984A4 (en) * | 2019-09-09 | 2023-10-18 | The University of Chicago | Combination therapy for the treatment of migraines |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ197996A (en) | 1980-08-12 | 1985-08-16 | Glaxo Group Ltd | 1-(3-(omega-aminoalkyl)-1h-indol-5-yl)alkanamides |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| HU196752B (en) | 1983-12-06 | 1989-01-30 | Glaxo Group Ltd | Process for production of medical compositions containing indole-derivatives and these compounds |
| US5021428A (en) | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
| US5200413A (en) | 1987-01-05 | 1993-04-06 | Beecham Group P.L.C. | Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis |
| US5364863A (en) | 1987-09-08 | 1994-11-15 | Eli Lilly And Company | Specific 5-HT3 antagonists |
| DE3823378A1 (de) | 1988-07-09 | 1990-01-11 | Knoll Ag | (s)-emopamil zur anwendung bei der behandlung von migraene |
| US4916125A (en) | 1989-07-11 | 1990-04-10 | Sandoz Ltd. | Method of treating migraine |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| JP3122671B2 (ja) | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
| KR100215627B1 (ko) | 1990-06-07 | 1999-08-16 | 레슬리 제인 에드워즈 | 치료용 헤테로사이클 화합물 |
| CA2020018A1 (en) | 1990-06-27 | 1991-12-28 | Don L. Simmons | Method and composition for treating the migraine complex |
| US5317103A (en) | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5491148A (en) | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
| ES2109362T3 (es) | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
| GB9113802D0 (en) | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| CA2084531A1 (en) | 1991-12-19 | 1993-06-20 | David W. Smith | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines |
| GB9221761D0 (en) | 1992-10-16 | 1992-12-02 | Glaxo Group Ltd | Chemical compounds |
| US5242949A (en) | 1992-03-13 | 1993-09-07 | Rugby-Darby Group Companies, Inc. | Treating classic migraine |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| DK154092D0 (da) | 1992-12-23 | 1992-12-23 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5468768A (en) | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| EP1131344B1 (en) * | 1998-11-19 | 2005-08-03 | ELAN CORPORATION, Plc | Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| JP2004532849A (ja) * | 2001-04-20 | 2004-10-28 | カイロン コーポレイション | 中枢神経系へのポリヌクレオチド薬剤の送達 |
| KR100484371B1 (ko) | 2001-10-25 | 2005-04-20 | 가부시키가이샤 아텍스 | 히터선부착 시트체의 제조방법 |
| CA2488497A1 (en) * | 2002-06-11 | 2003-12-18 | The Burnham Institute | Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7994127B2 (en) * | 2007-06-08 | 2011-08-09 | Massachusetts Institute Of Technology | Treatment of rett syndrome |
| WO2009005673A1 (en) * | 2007-06-28 | 2009-01-08 | Schering Corporation | Anti-igf1r |
| US8197858B2 (en) * | 2009-02-06 | 2012-06-12 | Mark John Zamoyski | Bone microenvironment modulated seizure treatments |
-
2012
- 2012-07-20 DK DK12817792.0T patent/DK2734634T3/da active
- 2012-07-20 AU AU2012287120A patent/AU2012287120B2/en active Active
- 2012-07-20 PL PL12817792T patent/PL2734634T3/pl unknown
- 2012-07-20 WO PCT/US2012/047683 patent/WO2013016223A2/en not_active Ceased
- 2012-07-20 US US14/234,276 patent/US9399053B2/en active Active
- 2012-07-20 ES ES12817792T patent/ES2751388T3/es active Active
- 2012-07-20 EP EP12817792.0A patent/EP2734634B1/en active Active
- 2012-07-20 EP EP19192519.7A patent/EP3628325A1/en not_active Withdrawn
-
2016
- 2016-06-02 US US15/171,327 patent/US9827294B2/en active Active
-
2017
- 2017-05-23 AU AU2017203461A patent/AU2017203461B2/en active Active
- 2017-10-24 US US15/791,802 patent/US10391150B2/en active Active
-
2018
- 2018-11-27 AU AU2018271278A patent/AU2018271278B2/en active Active
-
2019
- 2019-08-26 US US16/551,032 patent/US20190374612A1/en not_active Abandoned
-
2020
- 2020-08-28 AU AU2020223768A patent/AU2020223768A1/en not_active Abandoned
-
2021
- 2021-02-22 US US17/249,123 patent/US20210205414A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9827294B2 (en) | 2017-11-28 |
| AU2018271278A1 (en) | 2018-12-20 |
| WO2013016223A3 (en) | 2013-04-04 |
| EP2734634B1 (en) | 2019-08-21 |
| US20160263194A1 (en) | 2016-09-15 |
| AU2012287120A1 (en) | 2014-03-06 |
| EP3628325A1 (en) | 2020-04-01 |
| WO2013016223A2 (en) | 2013-01-31 |
| AU2017203461B2 (en) | 2018-09-06 |
| US10391150B2 (en) | 2019-08-27 |
| AU2012287120B2 (en) | 2017-02-23 |
| PL2734634T3 (pl) | 2020-03-31 |
| AU2017203461A1 (en) | 2017-06-08 |
| AU2018271278B2 (en) | 2020-05-28 |
| EP2734634A2 (en) | 2014-05-28 |
| US20180036380A1 (en) | 2018-02-08 |
| US9399053B2 (en) | 2016-07-26 |
| US20140294761A1 (en) | 2014-10-02 |
| EP2734634A4 (en) | 2015-06-10 |
| US20210205414A1 (en) | 2021-07-08 |
| ES2751388T3 (es) | 2020-03-31 |
| AU2020223768A1 (en) | 2020-09-17 |
| US20190374612A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020510I1 (lt) | Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui | |
| CY2019015I1 (el) | Χρηση πυριτικου ζιρκονιου για τη θεραπεια της υπερκαλιαιμιας | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| HRP20180237T1 (hr) | Metode za liječenje hcv-a | |
| DK3305317T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| DK3590928T3 (da) | Pyrimidinderivater til behandling af virusinfektioner | |
| DK2718404T3 (da) | Fremgangsmåde til fremstilling af flydende carbonhydrider | |
| DK2635282T3 (da) | Sammensætninger til behandling af myelofibrose | |
| CO6890100A2 (es) | Tratamientos de combinación para hepatitis c | |
| DK2785801T4 (da) | Fremgangsmåde til formindskelse af isdannelse på et underlag | |
| DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
| LT2928477T (lt) | Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui | |
| IL231092A0 (en) | Treatment of rhinitis | |
| DK2773648T3 (da) | Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion | |
| DK2807170T3 (da) | Phragmalin-limonoider til behandlingen af seksuel dysfunktion | |
| DK2906219T3 (da) | Orvepitant til behandling af kronisk pruritus | |
| IL231907B (en) | Compounds and compositions for treatment of transthyretin-associated amyloidosis | |
| LT2812013T (lt) | Kompozicija, skirta džs gydymui | |
| DK2701707T3 (da) | Fremgangsmåde til behandling af dyskinesi | |
| DK3524260T3 (da) | Farmaceutiske sammensætninger til behandling af manglende appetit | |
| DK2705847T3 (da) | Sammensætning til behandling af psoriasis | |
| DK3202769T3 (da) | Fremgangsmåde til oprensning af phosphaplatinforbindelser | |
| DK3536410T3 (da) | Fremgangsmåde til behandling af affaldsgenstande |